Myelodysplastic Syndromes in the Elderly-Reference-Cited by-同舟云学术

Myelodysplastic Syndromes in the Elderly

Published:2001-01 Issue:1 Volume:8 Page:79-102
ISSN:1073-2748
Container-title:Cancer Control
language:en
Short-container-title:Cancer Control

Author:

Saba Hussain I.¹

Affiliation:

1. MDS Center of Excellence and the Malignant Hematology Program at the H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida, and the Hematology/Oncology Program at the James A. Haley Veterans Hospital, Tampa, Fla.

Publisher

SAGE Publications

Subject

Oncology,Hematology,General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/107327480100800112

Reference134 articles.

1. Excessive Proliferation Matched by Excessive Apoptosis in Myelodysplastic Syndromes: The Cause-Effect Relationship

2. Extensive apoptosis of bone marrow cells as evaluated by the in situ end-labelling (ISEL) technique may be the basis for ineffective haematopoiesis in patients with myelodysplastic syndromes

3. Biologic characteristics of patients with hypocellular myelodysplastic syndromes

4. Prevalence and Causes of Anaemia in a Geriatric Hospitalized Population

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subjects with chronic lymphocytic leukaemia-like B-cell clones with stereotyped B-cell receptors frequently show MDS-associated phenotypes on myeloid cells;British Journal of Haematology;2014-09-24

2. Supportive Care in Myelodysplastic Syndrome;Advances in Malignant Hematology;2011-03-24

3. Telomere dysfunction induces environmental alterations limiting hematopoietic stem cell function and engraftment;Nature Medicine;2007-05-07

4. Decitabine in Myelodysplastic Syndromes;Seminars in Hematology;2005-07

5. The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future;Leukemia Research;2004-09